Abstract
Background Fecal Microbiota Transplant (FMT) has proven effective in treating recurrent Clostridioides difficile infection (rCDI) and has shown some success in treating inflammatory bowel diseases (IBD). There is emerging evidence that host engraftment of donor taxa is a tenet of successful FMT. However, there is little known regarding predictors of engraftment. We undertook a double-blind, randomized, placebo-controlled pilot study to characterize the response to FMT in children and young adults with mild to moderate active Crohn’s disease (CD) and ulcerative colitis (UC).
Results Subjects with CD or UC were randomized to receive antibiotics and weekly FMT or placebo in addition to baseline medications. The treatment arm received seven days of antibiotics followed by FMT enema and then capsules weekly for seven weeks. We enrolled four subjects with CD and 11 with UC, ages 14-29 years. Due to weekly stool sampling, we were able to create a time series of alpha diversity, beta diversity and engraftment as they related to clinical response. Subjects exhibited a wide range of microbial diversity and donor engraftment as FMT progressed. Specifically, engraftment ranged from 26% to 90% at week 2 and 3% to 92% at two months. Consistent with the current literature, increases over time of both alpha diversity (p< 0.05) and donor engraftment (p< 0.05) correlated with improved clinical response. Additionally, our weekly time series enabled an investigation into the clinical and microbial correlates of engraftment at various time points. We discovered that the post-antibiotic but pre-FMT time point, often overlooked in FMT trials, was rich in microbial correlates of eventual engraftment. Greater residual alpha diversity after antibiotic treatment was positively correlated with engraftment and subsequent clinical response. Interestingly, a transient rise in the relative abundance of Lactobacillus was also positively correlated with engraftment, a finding that we recapitulated with our analysis of another FMT trial with publicly available weekly sequencing data.
Conclusions We found that higher residual alpha diversity and Lactobacillus blooms after antibiotic treatment correlated with improved engraftment and clinical response to FMT. Future studies should closely examine the host microbial communities pre-FMT and the impact of antibiotic preconditioning on engraftment and response.
Competing Interest Statement
AB receives research support as a subinvestigator on protocols for Janssen, Abbvie, Takeda, Buhlmann, Arena, Eli Lilly, Bristol Myers Squibb, PROCISE diagnostics. AB receives consulting revenue from Takeda, Best Doctors, Eli Lilly, and Fresenius Kabi. AB received an honorarium from Boston University and Royalties from Up To Date.
Clinical Trial
NCT02330653
Funding Statement
This research was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (award 5K12HD052896 to Gary R. Fleisher, MD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the protocol, applicable ICH Guidelines, Good Clinical Practice and the World Medical Association (WMA) Declaration of Helsinki and its amendments concerning medical research in humans. In accordance with guidelines and U.S. Code of Federal Regulations applicable to clinical studies, the protocol and informed consent/assent forms were reviewed and approved by the Boston Children's Hospital Institutional Review Board (IRB). The investigator informed the IRB and FDA of subsequent protocol amendments and reportable events as defined by IRB policy and FDA regulation. All patients and/or their guardians consented to participate in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
jason.zhang{at}childrens.harvard.edu
athos.bousvaros{at}childrens.harvard.edu
michael.docktor{at}childrens.harvard.edu
abby.kaplan2{at}childrens.harvard.edu
paul.rufo{at}childrens.harvard.edu
mleier{at}princeton.edu
madisonweatherly{at}gmail.com
lori.zimmerman{at}childrens.harvard.edu
lttnguye{at}mit.edu
brendajbarton{at}gmail.com
george.russell{at}mainehealth.org
ejalm{at}mit.edu
stacy.kahn{at}childrens.harvard.edu
Data Availability
All data produced in the present study are contained in the manuscript, available in the supplements, or are available upon reasonable request to the authors.
List of Abbreviations
- CD
- Crohn disease;
- FMT
- Fecal Microbiota Transplant;
- PUCAI
- Pediatric Ulcerative Colitis Activity Index;
- PCDAI
- Pediatric Crohn Disease Activity Index;
- IBD
- Inflammatory Bowel Disease;
- IBS
- Irritable Bowel Syndrome;
- rCDI
- recurrent Clostridiodes difficile Infection;
- UC
- Ulcerative Colitis
